Clinical trials: Mental Depression
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Depression / Major Depressive Disorder, Anxiety
Activating Voice Journaling for Mental Health With Voice Biomarkers
This retrospective observational study evaluated the relationship between voice characteristics and self-reported mental health symptoms using longitudinal data collected through the Kintsugi Voice Journaling app.
- Trial name
- NCT07789808
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Depression, Bipolar
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.
- Trial name
- NCT01396447
- Testing
- Cariprazine
- Where
- 88 sites in United States, Bulgaria and 4 more
- Volunteers
- 584 people
- Sponsor
- Forest Laboratories
Depression, Depressive Disorder
A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model
The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a…
- Conditions
- Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
- Trial name
- FTP (NCT05685758)
- Testing
- FTP-based therapeutic mobile-app
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Hedonia Ltd
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Bipolar Disorder, Depression
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I…
- Trial name
- NCT02670538
- Testing
- Cariprazine
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 493 people
- Sponsor
- Forest Laboratories
Depression, Depressive Disorder
Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder
Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- ELATED-4 (NCT06934135)
- Testing
- Bilateral Near-Infrared Transcranial Photobiomodulation (tPBM)
- Where
- 2 sites in Peru
- Volunteers
- 50 people
- Sponsor
- NeuroThera DE
Depression, Post Traumatic Stress Disorder
Ketamine and Epigenetic Aging
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age…
- Trial name
- NCT05294835
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Anxiety, Microbiome
Microbiome, Anxiety and Cognitive Orientation Study
Mounting evidence shows that the gut microbiome plays an important role in communication within the gut-brain axis. However, the relationship between gut microbiota and their influence on anxiety is still not fully understood.
- Conditions
- Anxiety, Microbiome, Mood Disorders, Neurodegeneration
- Trial name
- MACO (NCT05388630)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Endominance
Depression
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.
- Trial name
- NCT00864981
- Testing
- Bupropion HCI ER Tablets, 150 mg; EON Labs Inc., WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder (MDD)
A Phase II Study to Evaluate NH102 for Depression
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine .
- Trial name
- NH102-21 (NCT06842992)
- Testing
- NH102, Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- 24 sites in China
- Volunteers
- 243 people
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Major Depressive Disorder
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
- Trial name
- NCT00599911
- Testing
- Lu AA24530, Duloxetine
- Where
- 72 sites in Australia, Austria and 15 more
- Volunteers
- 652 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Study to Evaluate the Effect of Genotype on LY2216684
The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.
- Trial name
- NCT01460381
- Testing
- LY2216684, Quinidine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00771134
- Testing
- Lu AA39959, Quetiapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.
- Trial name
- VLZ-MD-21 (NCT01878292)
- Testing
- Vilazodone
- Where
- 52 sites in United States
- Volunteers
- 529 people
- Sponsor
- Forest Laboratories
Nervousness, Restlessness
Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness
Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12. Each patient is treated with NPB. No placebo group is established.
- Conditions
- Nervousness, Restlessness, Depression (Agitated), Affective Disorders
- Trial name
- NCT01125579
- Where
- Germany
- Volunteers
- 115 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder and Anxiety Disorders
First Time in Human Study
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
- Trial name
- FTIM (NCT01031186)
- Testing
- GSK356278
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fasting conditions.
- Trial name
- NCT00913718
- Testing
- Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sandoz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.